CytomX Therapeutics (CTMX) Share-based Compensation (2014 - 2026)

CytomX Therapeutics (CTMX) has 13 years of Share-based Compensation data on file, last reported at $4.7 million in Q1 2026.

• Quarterly Share-based Compensation rose 134.36% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (up 7.3% YoY) and the FY2025 annual result came in at $7.3 million, down 4.8% from the prior year.
• Share-based Compensation grew to $4.7 million in Q1 2026, from $1.5 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $4.7 million in Q1 2026 to a low of -$10.5 million in Q4 2022.
• A 5-year average of $1.2 million and a median of $1.9 million in 2024 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2022 — Share-based Compensation sank 396.28% — and 2026, when it jumped 134.36%.
• Tracing CTMX's Share-based Compensation over 5 years: stood at -$10.5 million in 2022, then jumped by 124.3% to $2.6 million in 2023, then fell by 26.18% to $1.9 million in 2024, then fell by 21.5% to $1.5 million in 2025, then soared by 218.19% to $4.7 million in 2026.
• The last three Share-based Compensation figures came in at $4.7 million (Q1 2026), $1.5 million (Q4 2025), and $800000.0 (Q3 2025), per Business Quant data.